Ohio State researchers design a viral vector to treat a genetic form of blindness

Researchers at Ohio State University Medical Center and Nationwide Children's Hospital have developed a viral vector designed to deliver a gene into the eyes of people born with an inherited, progressive form of blindness that affects mainly males.

The vector is part of a clinical trial investigating the use of gene therapy to cure choroideremia, a disease that affects an estimated 100,000 people worldwide. The trial is being conducted by researchers at the University of Oxford in England.

The vector was designed by Dr. Matthew During, professor of , immunology and and of neuroscience and neurological surgery at Ohio State, in collaboration with Robert MacLaren, professor of ophthalmology at the University of Oxford, who also leads the trial.

Researcher Dr. K. Reed Clark, director of the Clinical Manufacturing Facility at the Center for Gene Therapy, Nationwide Children's Hospital, and his team produced the clinical-grade vector that is administered to patients in the trial.

During, who is also a visiting professor of translational neuroscience at Oxford, was in the operating room during the pioneering surgery. "I and my colleagues are excited about contributing to this significant ," During says. "We have worked for many years to engineer and optimize viruses to safely deliver genes to humans, and the eye is an ideal in many ways. The clinical vector manufacturing facility at Nationwide Children's Hospital is outstanding, and Dr. Clark and his team deserve congratulations for providing a clinical vector that for the first time offers these patients the possibility of an ."

During and his colleagues designed the to infect the light-sensitive photoreceptor cells that line the back of the eye and make up the retina. Choroideremia causes a degeneration of these photosensitive and progressive blindness. The diagnosis is usually made in childhood and leads to blindness by around age 45

"This trial represents the first attempt to treat this disease and the first time that gene therapy has been directed towards the of the human retina," During says. "We believe it holds great promise for the treatment of other genetic causes of blindness such as retinitis pigmentosa."

The trial's 12 patients will be treated in one eye. It will take 24 months to know whether the gene-therapy treatment has stopped the degeneration. The trial builds on gene-therapy research performed in collaboration with Professor Miguel Seabra at Imperial College London, along with During and Clark at Ohio State.

"This disease has been recognized as an incurable form of blindness for over a hundred years," MacLaren says. "I cannot describe the excitement in thinking that we have designed a genetic treatment that could potentially stop it in its tracks with one single injection."

Related Stories

First clinical trial of gene therapy for childhood blindness

date May 01, 2007

The first clinical trial to test a revolutionary treatment for blindness in children has been announced by researchers at UCL (University College London). The trial, funded by the Department of Health, is the first of its ...

Recommended for you

Lowering risk of a major eye disease

date May 20, 2015

Age-related macular degeneration (AMD), a chronic, progressive disease, is a leading cause of blindness among people aged 65 and older. Vision impairment due to advanced AMD significantly reduces quality ...

Age-related macular degeneration, mortality linked

date May 12, 2015

(HealthDay)—Age-related macular degeneration (AMD) is a predictor of poor survival, especially among women aged 80 years and older, according to a study published online May 4 in the Journal of the American Ge ...

Short-sightedness becoming more common across Europe

date May 11, 2015

Myopia or short-sightedness is becoming more common across Europe, according to a new study led by King's College London. The meta-analysis of findings from 15 studies by the European Eye Epidemiology Consortium ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.